Equity
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss
Edwards Lifesciences AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss decreased by 8.3% to $1.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 71.1%, from $3.80M to $1.10M.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ4 2017
Last reportedQ1 2026May 6, 2026
Metric ID:
afs_debt_securities_unrealized_loss_12m_plus_accHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $3.20M | $5.50M | $30.00M | $60.00M | $54.10M | $48.20M | $38.30M | $25.60M | $17.90M | $12.70M | $6.80M | $5.20M | $3.80M | $2.70M | $1.90M | $1.20M | $1.10M |
| QoQ Change | — | — | — | — | +71.9% | +445.5% | +100.0% | -9.8% | -10.9% | -20.5% | -33.2% | -30.1% | -29.1% | -46.5% | -23.5% | -26.9% | -28.9% | -29.6% | -36.8% | -8.3% |
| YoY Change | — | — | — | — | — | — | — | >999% | +776.4% | +27.7% | -57.3% | -66.9% | -73.7% | -82.2% | -79.7% | -78.8% | -78.7% | -72.1% | -76.9% | -71.1% |
Range$0.00 – $60.00M
Avg YoY Growth+127.5%
Median YoY Growth-72.1%
Current Streak13 quarters decline
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) accumulated loss?
- Edwards Lifesciences (EW) reported afs and trading securities - unrealized loss position (>=12 months) accumulated loss of $1.10M in Q1 2026.
- How has Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) accumulated loss changed year-over-year?
- Edwards Lifesciences's afs and trading securities - unrealized loss position (>=12 months) accumulated loss decreased by 71.1% year-over-year, from $3.80M to $1.10M.